within Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA06_Brolucizumab;

model Brolucizumab
  extends Pharmacolibrary.Drugs.ATC.S.S01LA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Brolucizumab</td></tr><tr><td>ATC code:</td><td>S01LA06</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brolucizumab is a humanized single-chain antibody fragment (scFv) that targets vascular endothelial growth factor A (VEGF-A). It is used for the treatment of neovascular (wet) age-related macular degeneration (AMD) and is administered by intravitreal injection. Brolucizumab is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with neovascular (wet) age-related macular degeneration, receiving intravitreal injection of brolucizumab at the recommended clinical dose.</p><h4>References</h4><ol><li><p>Nagaoka, K, et al., &amp; Aizawa, K (2025). Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis. <i>International journal of molecular sciences</i> 26(2) â€“. DOI:<a href=\"https://doi.org/10.3390/ijms26020556\">10.3390/ijms26020556</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39859273/\">https://pubmed.ncbi.nlm.nih.gov/39859273</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Brolucizumab;
